Treatment of Stem Cell Transplant Patients Using CD34-Selected Stem Cells to Reduce Graft-Versus-Host Disease

What this Trial Is About

This research aims to evaluate a special method of treating donor stem cells to reduce the risks of graft-versus-host disease GvHD and transplant failure in patients needing a stem cell transplant. The study includes patients whose disease requires transplantation but lack a perfectly matched donor, or who have had a previous transplant with mixed donor and patient bone marrow cells or poor bone marrow function. The goal is to improve transplant outcomes by minimizing donor cells that may attack the patients tissues. Participants receive stem cells collected from a close relative donor through a device called the CliniMACS CD34 Reagent System. This machine separates stem cells by binding them to a special protein, reducing the donor T cells that cause GvHD. The study has three groups Cohort 1 includes patients receiving a transplant after conditioning treatment Cohort 2 includes patients needing extra stem cells without conditioning Cohort 3 includes patients needing extra stem cells with conditioning. The stem cells may be given fresh or frozen. Participants will have follow-up exams around days 28, 60, 100, 180, and 365 after transplant to monitor transplant success and any complications like GvHD or infections. Health information will be collected for one year to assess survival, relapse, and adverse events. Those without GvHD may have fewer tests. The study lasts about one year, focusing on the rate of stem cell engraftment and the severity of acute GvHD.

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection